New Drug to Stop 'Ozempic Butt' Muscle Loss Side Effect of Obesity Jabs

Why It Matters

Maintaining lean mass improves functional health and mitigates cosmetic side effects, potentially expanding the appeal and safety profile of GLP‑1 weight‑loss programs. If validated, apitegromab could become a standard adjunct, opening a new market segment for muscle‑preserving agents.

Key Takeaways

• Apitegromab preserved ~1.9 kg muscle in GLP‑1 trial participants.
• Muscle loss accounted for one‑third of total weight loss on GLP‑1s.
• Trial used Mounjaro; 55% more lean mass vs placebo.
• Drug blocks muscle‑breakdown protein; also studied for other disorders.
• Larger, longer studies required before clinical adoption.

Pulse Analysis

GLP‑1 receptor agonists such as Ozempic, Wegovy and Mounjaro have reshaped obesity treatment by delivering rapid, appetite‑suppressing weight loss. While effective at reducing fat, clinicians have observed that up to a third of the total weight shed can be lean tissue, leading to concerns about muscle weakness and the so‑called “Ozempic butt.” This muscle depletion not only affects physical performance but also fuels a growing cosmetic anxiety among patients, prompting plastic surgeons to report a surge in corrective consultations.

Enter apitegromab, an experimental monoclonal antibody that inhibits myostatin‑related pathways responsible for muscle breakdown. In a six‑month, double‑blind study involving 102 primarily female participants on Mounjaro, the drug enabled subjects to retain roughly 1.9 kg more muscle than those on placebo, translating to 55% higher lean‑mass preservation. Administered intravenously during the trial, the manufacturer is exploring a self‑injectable pen to mirror the convenience of existing GLP‑1 pens. Beyond obesity, apitegromab is being evaluated for conditions like spinal muscular atrophy, suggesting a broader therapeutic relevance.

If subsequent phase‑III trials confirm these early signals, apitegromab could become the first adjunct specifically targeting muscle loss in weight‑loss regimens. This would not only improve patient outcomes—enhancing strength, metabolic health, and quality of life—but also differentiate GLP‑1 products in a crowded market. Payers may view the combination as a value‑added therapy, potentially influencing reimbursement policies and prompting pharmaceutical firms to develop companion muscle‑preserving agents. However, regulatory approval will hinge on robust evidence of long‑term safety and functional benefits, underscoring the need for expanded research.